Core Viewpoint - BeiGene's stock price has shown significant volatility, with a year-to-date increase of 73.42%, but a recent decline in the short term, indicating potential market fluctuations and investor sentiment changes [1][2]. Group 1: Stock Performance - As of October 20, BeiGene's stock price was 279.24 CNY per share, with a market capitalization of 430.22 billion CNY [1]. - The stock has experienced a 1.73% decline over the last five trading days and an 11.51% decline over the last 20 days, despite a 11.80% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) once, with the last appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A, holding 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选, the sixth largest shareholder, reduced its holdings by 50% to 3 million shares [2]. - 新进股东, 南方中证500ETF, holds 1.7259 million shares, while 香港中央结算有限公司 has exited the top ten shareholders list [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （前稱BeiGene, Ltd. 百濟神州有限公司） （先前於開曼群島註冊成立的有限公司，並已在瑞士存續註冊） （股份代號：06160） 變更英文公司名稱及英文股份簡稱 本公司於香港聯交所的股份代碼維持不變，仍為「06160」。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年10月17日 變更英文公司名稱 如該公告所披露，公司的英文名稱已由BeiGene, Ltd. 變更為BeOne Medicines Ltd.，自2025年5月27日生效（瑞士時間）。 本公司欣然宣佈，香港公司註冊處處長已於2025年10月2日發出註冊非香港公司 變更名稱註冊證明書，證明BeOne Medicines Ltd.已根據香港法例第622章《公司 條例》第16部在香港註冊為本公司英文名稱。 變更英文股份簡稱 公司英文名稱變更完成後，於香港聯交所進行股 ...

Core Viewpoint - The company BeiGene, Ltd. will change its English name to BeOne Medicines Ltd., effective May 27, 2025 (Swiss time) [1] Group 1 - Following the name change, the English stock trading abbreviation on the Hong Kong Stock Exchange will change from "BEIGENE" to "BEONE MEDICINES," effective from 9:00 AM on October 22, 2025 (Hong Kong time) [1] - The Chinese stock trading abbreviation on the Hong Kong Stock Exchange will remain unchanged as "百济神州" [1]

Core Viewpoint - The company Beigene has completed its name change, and its English stock trading abbreviation on the Hong Kong Stock Exchange will change from "BEIGENE" to "BEONE MEDICINES" effective from October 22, 2025 [1] Group 1 - The English stock trading abbreviation will be updated to reflect the new company name [1] - The Chinese stock trading abbreviation will remain unchanged as "百济神州" [1]

Core Viewpoint - The company Beigene has completed its name change, and its stock trading name on the Hong Kong Stock Exchange will change from "BEIGENE" to "BEONE MEDICINES" effective from October 22, 2025 [1] Company Summary - The English stock trading name change will take effect at 9:00 AM Hong Kong time on October 22, 2025 [1] - The Chinese stock trading name will remain unchanged as "百济神州" [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （前稱BeiGene, Ltd. 百濟神州有限公司） （先前於開曼群島註冊成立的有限公司，並已在瑞士存續註冊） （股份代號：06160） 變更英文公司名稱及英文股份簡稱 茲提述BeOne Medicines Ltd.百濟神州有限公司（「本公司」）日期為2025年5月27日 的公告，內容有關（其中包括）完成遷址及存續及公司英文名稱變更（「該公告」）。 本公司欣然宣佈，香港公司註冊處處長已於2025年10月2日發出註冊非香港公司 變更名稱註冊證明書，證明BeOne Medicines Ltd.已根據香港法例第622章《公司 條例》第16部在香港註冊為本公司英文名稱。 變更英文股份簡稱 公司英文名稱變更完成後，於香港聯交所進行股份交易的英文股份簡稱將由 「BEIGENE」變更為「BEONE MEDICINES」，自2025年10月22日星期三上午九時 ...

Core Insights - The 2025 Sustainable Global Leaders Conference is being held in Shanghai from October 16 to 18, highlighting the importance of sustainable development and innovation in the financial sector [1] - Guo Chuan Zhou, Chairman of Yuekai Securities, emphasized the need for "patient capital" to support transformation and long-term development in technology finance [2] Company Focus - Yuekai Securities is strategically positioned in the Guangzhou Economic and Technological Development Zone, a key area in the Guangdong-Hong Kong-Macao Greater Bay Area known for its economic scale and technological innovation [2] - The company is focusing on three main levels of service in technology finance, with "transformation" being the primary task [2] Investment Strategy - The core approach of Yuekai Securities in serving the technology industry is "investment-led," aiming to drive growth through strategic investments [2] - The investment segment has been concentrating on "high-end" fields, with notable projects including investments in leading biopharmaceutical companies listed on the Sci-Tech Innovation Board [2]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.42% on October 16, with a trading volume of 1.486 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 15, 2024, the fund's shares reached 8.213 billion, with a total size of 7.102 billion yuan, reflecting a significant increase of 1977.25% in shares and 1779.88% in size compared to December 31, 2023 [1] Fund Performance - The current fund manager, Ma Jun, has achieved a return of 68.94% since taking over the fund on January 3, 2024 [2] - The ETF's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2] Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 30.962 billion yuan, averaging 1.548 billion yuan per day [1] - Since the beginning of the year, the ETF has seen a total trading amount of 222.219 billion yuan over 189 trading days, averaging 1.176 billion yuan per day [1]

专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 10月16日至18日，2025可持续全球领导者大会在上海世博园区召开。粤开证券董事长郭川舟受邀出席大 会，并做主旨演讲。 他介绍，粤开证券背靠广州经开区——这一粤港澳大湾区内经济总量与科技创新水平均位居前列的核心 区域。基于此，公司在服务科技金融方面主要从三个层面展开，其中"转型"是首要任务。自2017年起， 集团及粤开证券在战略与主营业务上实现了全面转型。八年来，通过持续收购与整合，包括完成对粤开 证券的并购，公司构建了新的主营业务生态，目前旗下拥有三家上市公司，覆盖能源发电、生物医疗器 械及新能源板块，并成功发行了广东省首单产业园区REIT。集团亦是中国服务业企业500强及全国唯一 一家"双百企业"区属国企。 在服务科技产业的具体模式上，郭川舟指出是以"投资引领"为核心。他举例称，自并购粤开证券后，投 资板块持续聚焦"高精尖"领域，代表性项目包括投资了科创板生物医药市值领军企业百济神州，以及小 鹏汽车、文远知行等知名公司。持续的收并购不仅是资产提升、实现产业投资退出 ...

Core Viewpoint - BeiGene's stock has shown significant volatility, with a year-to-date increase of 78.46%, but a recent decline over the past five and twenty trading days [1] Group 1: Stock Performance - As of October 16, BeiGene's stock price was 287.36 CNY per share, with a market capitalization of 442.73 billion CNY [1] - The stock experienced a 2.03% increase during the trading session on October 16, with a trading volume of 2.47 billion CNY and a turnover rate of 0.76% [1] - Year-to-date, the stock has risen by 78.46%, but it has decreased by 5.62% over the last five trading days and 9.35% over the last twenty trading days [1] Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03% [2] - The net profit attributable to shareholders for the same period was 450 million CNY, showing a significant increase of 115.63% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of BeiGene's shareholders was 23,300, a decrease of 3.90% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.11% to 4,976 shares [2] - Among the top ten circulating shareholders, notable changes included an increase in holdings by China Europe Medical Health Mixed A and a decrease by Wan Jia You Xuan [2]